Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.26
  • Today's Change0.11 / 1.79%
  • Shares traded26.67m
  • 1 Year change-8.48%
  • Beta0.5447
Data delayed at least 15 minutes, as of Jul 05 2024 08:11 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

  • Revenue in HKD (TTM)34.79bn
  • Net income in HKD6.51bn
  • Incorporated1992
  • Employees23.50k
  • Location
    CSPC Pharmaceutical Group LtdNo. 226 Huanghe StreetSHIJIAZHUANG 050035ChinaCHN
  • Phone+86 31 187037015
  • Fax+86 31 187039608
  • Websitehttps://www.cspc.com.hk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Roivant Sciences Ltd974.53m33.96bn60.46bn845.002.071.421.8262.045.075.070.15717.400.0260.81872.97147,686.4088.04--103.92--87.53--3,390.53--25.10--0.0642--103.65--487.06------
Innovent Biologics Inc6.67bn-1.10bn61.95bn4.87k--4.46--9.04-0.7001-0.70014.278.300.32480.94817.851,368,407.00-5.38-13.06-6.80-15.8581.6984.51-16.56-43.442.78-162.510.2242--36.21265.7952.83--34.60--
Aurobindo Pharma Ltd27.12bn2.97bn67.88bn15.69k23.182.4615.672.5354.1254.12494.54509.350.68271.386.25--7.469.2410.3513.4356.5454.1510.9312.721.1816.120.1821--16.688.1964.626.0617.96--
Lupin Ltd18.71bn1.79bn69.52bn18.97k42.005.6125.614.0141.8941.89437.85313.600.85241.414.36--8.241.4313.342.2266.8059.709.672.040.99918.640.168979.2820.256.41345.1530.18-1.179.86
Swedish Orphan Biovitrum AB (publ)17.20bn1.59bn71.81bn1.75k44.562.6117.594.226.196.1969.32105.590.36031.504.7213,058,130.003.335.934.437.6076.6077.429.2516.610.49943.560.34870.0017.7419.34-8.68-0.072953.61--
Kyowa Kirin Co Ltd22.00bn4.02bn72.29bn5.97k19.011.8615.123.49154.53154.53845.281,577.380.4551.614.2476,040,840.008.326.289.557.0874.0675.4518.2814.963.06--0.027247.2511.0110.2551.5510.5210.289.86
CSPC Pharmaceutical Group Ltd34.78bn6.51bn73.76bn23.50k11.21--12.472.100.54880.54882.93--------1,480,162.00--16.08--21.5771.5172.9519.2519.63------35.511.6612.16-3.5813.77-2.5825.33
Sichuan Biokin Pharmaceutical Co Ltd6.34bn4.72bn75.31bn2.09k16.0213.64--11.9210.9510.9514.7112.861.371.8541.292,828,652.00102.16--138.88--95.70--74.42--3.75828.870.1314---20.11---176.40------
Ipsen SA27.92bn5.21bn79.40bn5.33k15.462.4710.002.907.397.7239.6646.250.5541.995.23620,920.2010.489.7113.9313.3382.7282.7618.9116.020.98930.430.08919.234.757.084.039.75-8.653.71
Catalent Inc32.29bn-9.18bn79.86bn17.80k--2.82--2.47-6.48-6.4822.6920.060.39934.362.87232,303.40-11.362.88-12.913.2618.9631.03-28.446.351.740.01540.57970.00-11.2211.59-153.00--26.69--
Mankind Pharma Ltd9.66bn1.79bn80.16bn18.47k45.579.3037.208.4247.6947.69257.65233.73----------------68.94--18.79--2.37116.650.0212--18.12--49.23------
Recordati Industria Chmc Frmctc SpA18.06bn3.28bn85.99bn4.46k27.365.5718.894.801.791.799.928.810.51771.674.53480,087.109.4111.6712.1315.0267.8270.4318.1821.450.95187.550.488342.4612.369.0224.614.5081.685.46
Shionogi & Co Ltd21.07bn7.85bn88.94bn4.96k11.111.4210.274.22557.64557.641,499.184,357.540.31890.93783.7587,735,430.0011.7712.5713.4014.2486.7684.4336.9137.915.37--0.009226.771.973.41-12.403.382.1711.22
Data as of Jul 05 2024. Currency figures normalised to CSPC Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

14.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 06 Jun 2024342.84m2.88%
First Sentier Investors (Hong Kong) Ltd.as of 29 Feb 2024276.39m2.32%
First Sentier Investors (UK) IM Ltd.as of 29 Feb 2024191.42m1.61%
Norges Bank Investment Managementas of 31 Dec 2023170.52m1.43%
UBS Asset Management Switzerland AGas of 14 Jun 2024148.48m1.25%
BlackRock Fund Advisorsas of 14 Jun 2024147.30m1.24%
UBS Asset Management (Hong Kong) Ltd.as of 14 Jun 2024132.84m1.11%
Hang Seng Investment Management Ltd.as of 07 Jun 2024126.75m1.06%
GF Fund Management Co., Ltd.as of 31 Dec 2023110.81m0.93%
BlackRock Advisors (UK) Ltd.as of 14 Jun 2024110.52m0.93%
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.